The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation
Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, briefly discusses the outcomes of patients with acute myeloid leukemia (AML) harboring poor-risk cytogenetics and TP53 mutation treated with venetoclax-based regimens. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
